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Background
Therapeutic management of Mycobacterium avium
infection is inadequate due to patient non-compliance,
lengthy treatment regimen, multidrug associated toxic
side-effects etc. particularly in AIDS patients who are at
a greater risk of developing mycobacterial infection.
This study was designed to evaluate chemotherapeutic
potential of poly D, L-lactide-co-glycolide nanoparticles
against M. avium infection in mice.
Methods
Drug loaded nanoparticles were prepared by double
emulsification and characterized for their size, surface
morphology and sustained drug release. Pharmacoki-
netics of free and nanoencapsulated drugs were evalu-
ated after single oral dose administration and
therapeutic efficacy was assessed in M. avium infected
mice after 4 weeks of chemotherapy.
Results
Sustained release of various drugs was observed for 5-7
days as compared to 24h for free drugs in plasma and
various tissues. Eight weeks of chemotherapy resulted in
significant clearance of bacilli from lungs and spleen of
M. avium infected mice as compared to untreated con-
trols. 8 doses of PLGA nanoencapsulated M. avium
drugs depicted an equivalent therapeutic effect as that
of 56 doses of daily administered oral free drugs which
was evident from cfu enumeration data and lung histo-
pathology. Furthermore, nanoencapsulation was
observed to lessen the adverse drug interactions between
anti-retroviral and anti-M. avium drugs.
Conclusion
PLGA nanoparticle based drug delivery system showed
great potential to produce sustained release of anti-HIV
/ M. avium drugs. These studies hold promise to reduce
the frequency of drug dosages as well as alleviate
adverse drug interactions during the course of M. avium
and HIV therapy.
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